We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

1 hedge funds and large institutions have $13K invested in Alexion Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more capital invested

Capital invested by funds: $13K → $13K ($0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ALXN Hedge Fund Activity: Q1 2023 in Review

1 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2023, worth a combined $13K — unchanged from a quarter earlier.

Fund positioning in ALXN was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $13K of Alexion Pharmaceuticals stock for Q1 2023, unchanged quarter-over-quarter.
  • 0 funds opened new Alexion Pharmaceuticals positions in Q1 2023 and 0 closed out.

Based on aggregated 13F filings for Q1 2023.